Salute e Benessere

ECMO Machine Market worth US$0.86 billion by 2030 with 5.8% CAGR |…

Browse in-depth TOC on "ECMO Machine Market" Browse in-depth TOC on "ECMO Machine Market" 250 - Tables 50 - Figures 350 - Pages By product,the market of ECMO machines is divided into components and ECMO machines. In 2024, the components segment held the largest share of the global ECMO machines market. The component segment benefits from rapid innovation in oxygenator design, centrifugal pumps, and digital controllers. For example, polymethyl pentene (PMP) hollow-fiber...
PR Newswire
09/10/2025

Feminine Intimate Care Market to Reach $14 billion, Globally, by 2034 at 6.1%…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A291929 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A291929 Prime determinants of growth Growing disposable incomes, knowledge of personal cleanliness, and the desire for organic and natural products are the main factors propelling the market for feminine intimate care. Women's adoption of improved hygienic habits and the move toward...
PR Newswire
09/10/2025

Wearable Medical Devices Market Poised for USD 499.2 Billion by 2035, Growing at…

Why This Market Matters to CXOs Why This Market Matters to CXOs The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/wearable-medical-devices-market-2927/request-sample Free Sample Includes: Technological & Industry Momentum Strategic Opportunities for Business Leaders Expert Insights "Wearable medical devices are becoming the backbone of preventive and personalized...
PR Newswire
09/10/2025

Medical Aesthetics Market to Surge from US$ 18.48 Billion in 2024 to US$ 55.99…

Recent advancements, particularly in minimally invasive devices and AI-assisted treatment planning, are expanding the customer base beyond traditional dermatology practices to medical spas, beauty centers, and outpatient clinics. Recent advancements, particularly inminimally invasive devices and AI-assisted treatment planning,are expanding the customer base beyond traditional dermatology practices tomedical spas, beauty centers, and outpatient clinics. Download PDF Brochure:...
PR Newswire
09/10/2025

Cardiovascular Drugs Market to 2030: APAC Leads Growth and Telehealth Helps…

The Asia-Pacific region leads the cardiovascular drug market, driven by reforms and expanding healthcare infrastructure, which also boost opportunities for local companies and increase competition for international players. Japan's faster approval process supports the adoption of advanced therapies, including newer anticoagulants and metabolic treatments. TheAsia-Pacificregion leads the cardiovascular drug market, driven by reforms and expanding healthcare infrastructure, which also boost...
PR Newswire
09/10/2025

Hagar hf.: – Information on the publication of Q2 2025/26 results

Hagar hf. will publish its financial results for Q2 2025/26, covering the period 1 June to 31 August 2025, after market close on Thursday, 16 October 2025.A presentation meeting for investors and market participants will be held at Nauthóll, Nauthólsvegur 106, Reykjavík, on Friday, 17 October 2025, at 8:30 a.m.At the meeting, Finnur Oddsson, CEO, and Guðrún Eva Gunnarsdóttir, CFO, will present the company’s operations and financial performance and answer questions.The meeting will also...
Nasdaq GlobeNewswire
09/10/2025

Kimberly-Clark Launches Enhanced Global Partnerships to Advance Essential Care…

This announcement is a direct result of the Kimberly-Clark Foundation's recent sharpening of its strategic focus: to advance essential care for women and girls on their journeys through puberty and motherhood. The foundation will fund this three-year, $28.7 million commitment, which focuses on menstrual care and maternal & infant care. This announcement is a direct result of theKimberly-Clark Foundation 's recent sharpening of its strategic focus: to advance essential care for women and...
PR Newswire
09/10/2025

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

LuX-Valve Plus has successfully obtained this approval for commercial clinical application in mainland of GBA by leveraging its extensive successful clinical application experience, outstanding clinical performance, and unique and advanced product design in major countries/regions worldwide, including Asia-Pacific, North America, Europe, South America, and Middle East. Through this access pathway, LuX-Valve Plus is expected to initially meet the urgent and substantial treatment needs of patients…
PR Newswire
09/10/2025

Field Medical First-in-Human 6-Month Data Selected for Late-Breaking Clinical…

Field Medical will be featured across three sessions, including first-in-human six-month outcomes from its FieldForce™ Ablation System, the first focal contact-force PFA platform designed for VT, a pre-recorded live VT case and translational preclinical research. Field Medical will be featured across three sessions, including first-in-human six-month outcomes from its FieldForce™ Ablation System, the first focal contact-force PFA platform designed for VT, a pre-recorded live VT case and...
PR Newswire
09/10/2025

Consortium consisting of Nordic Capital and Permira receives final regulatory…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, 9 October, 2025– With reference to the announcements of 26 August 2025 (no. 24/2025 and no. 25/2025) and the announcement of 29 September 2025 (no. 27/2025) concerning the all-cash voluntary recommended public takeover offer to acquire all of the issued and outstanding...
Nasdaq GlobeNewswire
09/10/2025

Simple Life raises $35M Series B to scale its AI health coach for lasting weight…

"I'm hyped to back Simple through my fund HartBeat Ventures. Simple is truly changing the game in health, and HBV wants to be front row for that," said Kevin Hart, founder of Hartbeat Ventures. "I'm hyped to back Simple through my fund HartBeat Ventures. Simple is truly changing the game in health, and HBV wants to be front row for that," saidKevin Hart, founder of Hartbeat Ventures. Solving a$340 billionmarket gap Weight management is one of the largest consumer health...
PR Newswire
09/10/2025

Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the…

ADCE-D01 is currently being evaluated in the ADCElerate1 clinical trial, a first-in-human Phase I/II multicenter, open-label, dose escalation and expansion study evaluating ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS. The primary objective of the study is to evaluate the safety and tolerability of ADCE-D01. The secondary objectives are to characterize the pharmacokinetics and to evaluate the preliminary efficacy of ADCE-D01. The study is recruiting in the US…
PR Newswire
09/10/2025

Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting…

Operational Efficiencies and Focus on Profitability Drove Net Income of $1.5 Million, Adjusted EBITDA Increased 9% to $10 Million and Net Cash Used in Operations Improved by $34 Million Year-Over-YearCanadian Adult-Use Cannabis Gross Revenue Increased 12%, Maintaining the #1 Position in Revenue and Expanding Market Share; International Cannabis Revenue Grew 10% Year-Over-YearBalance Sheet Strengthened to $265 Million in Cash; Net Debt Reduced to $4 Million...
Nasdaq GlobeNewswire
09/10/2025

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new…

/Ridgefield, Connecticut, U.S.Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function. 1 Approval is based on results from two clinical trials, which showed reduction in Forced Vital Capacity decline with JASCAYD versus placebo in adults with idiopathic pulmonary fibrosis (IPF). 2,3 Nerandomilast is a new treatment option for adult patients with IPF with a well-tolerated safety profile. 2,3Boehringer Ingelheim’s JASCAYD ®...
Nasdaq GlobeNewswire
09/10/2025

Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting…

"With the validation of PrecisionSphere's capabilities and our proven track record of executing several key strategic partnerships each year, we are ready to expand patient access to advanced LAI treatments through new global strategic collaborations," said Dr. Fabrice Egros, President – Corporate Development, Lupin. "Our extensive in-house and successful alliance management capabilities will serve as a strategic advantage, as partners strive to deliver innovative LAI solutions to…
PR Newswire
09/10/2025

Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21…

Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent obesity related comorbiditiesAkero Therapeutics’s FGF21 analogue efruxifermin is the only treatment to show significant fibrosis regression in phase 2 in patients with compensated cirrhosis (F4)Novo Nordisk to acquire Akero Therapeutics for 54 USD per share (4.7 billion USD) in cash at closing with a contingent value right (CVR) of 6 USD per share...
Nasdaq GlobeNewswire
09/10/2025

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks Inc.(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer.In this role, Dr. Schayowitz will report directly to Zymeworks’ Chair & Chief Executive Officer, Kenneth Galbraith, and work...
Nasdaq GlobeNewswire
09/10/2025

Chance Pharma Announces Commercialization Agreement with Huadong Medicine for…

Mr. Liang Lv, Chairman and General Manager of Huadong Medicine, commented: "We see significant potential for CXG87 in respiratory treatment. This partnership will strategically enhance our respiratory pipeline and, by leveraging our nationwide commercial network and specialized promotion team, will enable CXG87 to achieve rapid market access and broad coverage upon launch. We are dedicated to building a strong and synergistic partnership with Chance, harnessing our respective strengths to…
PR Newswire
09/10/2025

Orexa Announces Positive Interim Data for its Phase 2 Trial in the Prevention of…

The clinical trial (EudraCT number 2022-503113-31-00-IN-002) is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of Orexa's lead compound ORE-001. The Study is enrolling 100 to 120 female patients undergoing gynecologic surgery requiring longitudinal laparotomy. It is being conducted at multiple centers in Germany with lead investigator Prof. Alexander Mustea from Universitätsklinikum Bonn (UKB). The clinical trial (EudraCT number...
PR Newswire
09/10/2025

Resolution Therapeutics announces upcoming presentations at the American…

Dr Paul Brennan MD, PhD, Clinical Lecturer in Hepatology, University of Dundee, UK, will present data from the University of Edinburgh's MATCH 2 clinical trial demonstrating that regenerative macrophage therapy (RMT) is associated with early changes in biomarkers associated with liver function (INR; dMELD), which in turn correlate with much longer survival in patients with advanced cirrhosis. Details below: DrPaul BrennanMD, PhD, Clinical Lecturer in Hepatology,University of Dundee, UK,...
PR Newswire
09/10/2025

Ariceum Therapeutics Data at the 2025 European Association of Nuclear Medicine…

Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study design of 225Ac-SSO110 in patients with ES-SCLC or MCC225Ac-SSO110 achieves superior pharmacokinetics with minimal re-distribution of Actinium-225 daughter isotopes and 100% survival in preclinical studiesInitial safety data from SANTANA-225 expected in 2026 BERLIN, Oct.09, 2025(GLOBE NEWSWIRE) --Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in...
Nasdaq GlobeNewswire
09/10/2025

Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for…

On track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026Planned UK trial to be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust, a European hub for advanced therapies, with participation from Dr. Andrew Furness at The Royal Marsden, a world-renowned centre for oncology and early-phase clinical research Oslo, Norway, 9 October 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic (“off-the-shelf”) T Cell...
Nasdaq GlobeNewswire
09/10/2025

Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE®…

Pratteln, Switzerland, October 9, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Biomedica for the distribution of AGAMREE® (vamorolone) in Russia, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.Under the terms of the agreement, Santhera will receive a percentage of net sales, in line with previous distribution agreements, with sales expected to begin in Q1 2026. This collaboration will enable...
Nasdaq GlobeNewswire
09/10/2025

Fagron reports solid third quarter performance with 6.4% revenue growth and…

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 9 October 2025 – 7:00 AM CET Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlookFagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2025. Key Highlights Q3 2025 organic growth at CER1 of 8.5% on a normalized basis2and 5.7% including the GLP-1 impact ...
Nasdaq GlobeNewswire
09/10/2025
Altri  Comunicati